JPWO2020227474A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020227474A5 JPWO2020227474A5 JP2021566152A JP2021566152A JPWO2020227474A5 JP WO2020227474 A5 JPWO2020227474 A5 JP WO2020227474A5 JP 2021566152 A JP2021566152 A JP 2021566152A JP 2021566152 A JP2021566152 A JP 2021566152A JP WO2020227474 A5 JPWO2020227474 A5 JP WO2020227474A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- polypeptide
- domain
- item
- natural
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025179511A JP2026021386A (ja) | 2019-05-08 | 2025-10-24 | Ｃｄ３３標的免疫療法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962845304P | 2019-05-08 | 2019-05-08 | |
| US62/845,304 | 2019-05-08 | ||
| US201962898392P | 2019-09-10 | 2019-09-10 | |
| US62/898,392 | 2019-09-10 | ||
| PCT/US2020/031780 WO2020227474A1 (en) | 2019-05-08 | 2020-05-07 | Cd33 targeted immunotherapies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025179511A Division JP2026021386A (ja) | 2019-05-08 | 2025-10-24 | Ｃｄ３３標的免疫療法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022531719A JP2022531719A (ja) | 2022-07-08 |
| JPWO2020227474A5 true JPWO2020227474A5 (https=) | 2023-06-23 |
| JP2022531719A5 JP2022531719A5 (https=) | 2023-06-23 |
| JP7765291B2 JP7765291B2 (ja) | 2025-11-06 |
Family
ID=73050903
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021566152A Active JP7765291B2 (ja) | 2019-05-08 | 2020-05-07 | Ｃｄ３３標的免疫療法 |
| JP2025179511A Pending JP2026021386A (ja) | 2019-05-08 | 2025-10-24 | Ｃｄ３３標的免疫療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025179511A Pending JP2026021386A (ja) | 2019-05-08 | 2025-10-24 | Ｃｄ３３標的免疫療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12552855B2 (https=) |
| EP (1) | EP3966251A4 (https=) |
| JP (2) | JP7765291B2 (https=) |
| KR (1) | KR20220031554A (https=) |
| CN (1) | CN114206928B (https=) |
| AU (1) | AU2020268379A1 (https=) |
| BR (1) | BR112021022356A2 (https=) |
| CA (1) | CA3139096A1 (https=) |
| IL (1) | IL287770A (https=) |
| MA (1) | MA55907A (https=) |
| MX (1) | MX2021013591A (https=) |
| SG (1) | SG11202111890RA (https=) |
| WO (1) | WO2020227474A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12291560B2 (en) | 2018-12-14 | 2025-05-06 | Regeneron Pharmaceuticals, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| CN116867806A (zh) * | 2021-02-10 | 2023-10-10 | 先声再明医药有限公司 | 人cd33抗体及其用途 |
| WO2023108158A2 (en) * | 2021-12-10 | 2023-06-15 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Methods and compositions for modulating the activity of a dimerizing agent regulated immunomodulatory complex |
| CN119546328A (zh) * | 2022-04-08 | 2025-02-28 | 再生元制药公司 | 多部分受体和信号传导复合物 |
| CA3248575A1 (en) * | 2022-04-22 | 2023-10-26 | Poplar Therapeutics, Inc. | SIALIC ACID-8 BINDING IMMUNOGLOBULIN-TYPE LECTIN-BINDING PROTEINS AND THEIR USES |
| US20250382636A1 (en) | 2022-05-26 | 2025-12-18 | Regeneron Pharmaceuticals, Inc. | Compositions for maintaining lentiviral vector and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100003253A1 (en) | 2002-11-08 | 2010-01-07 | Ablynx N.V. | Single domain antibodies directed against epidermal growth factor receptor and uses therefor |
| WO2015017214A1 (en) * | 2013-07-29 | 2015-02-05 | Bluebird Bio, Inc. | Multipartite signaling proteins and uses thereof |
| US20170081411A1 (en) * | 2014-03-15 | 2017-03-23 | Novartis Ag | Regulatable chimeric antigen receptor |
| EP3126390B2 (en) * | 2014-04-03 | 2026-01-07 | Cellectis | Cd33 specific chimeric antigen receptors for cancer immunotherapy |
| SI3151672T1 (sl) * | 2014-06-06 | 2021-03-31 | Bluebird Bio, Inc. | Izboljšani T-celični sestavki |
| SG10201913765YA (en) | 2014-07-21 | 2020-03-30 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
| EP3341410B1 (en) | 2015-08-24 | 2021-06-02 | Cellectis | Chimeric antigen receptors with integrated controllable functions |
| WO2017100403A1 (en) | 2015-12-08 | 2017-06-15 | Regents Of The University Of Minnesota | Human t cell derived from t cell-derived induced pluripotent stem cell and methods of making and using |
| KR20180096789A (ko) * | 2016-01-11 | 2018-08-29 | 인히브릭스, 인크. | 다가 및 다중특이적 41bb-결합 융합 단백질 |
| WO2017156479A1 (en) | 2016-03-11 | 2017-09-14 | Bluebird Bio, Inc. | Ror1 chimeric antigen receptors |
| MX2018010924A (es) | 2016-03-11 | 2019-02-13 | Bluebird Bio Inc | Células efectoras inmunitarias con edición genómica. |
| IL261713B2 (en) * | 2016-03-19 | 2023-09-01 | F1 Oncology Inc | Methods and preparations for the transfer of lymphocytes and their regulated expansion |
| WO2017180993A1 (en) * | 2016-04-14 | 2017-10-19 | Bluebird Bio, Inc. | Salvage chimeric antigen receptor systems |
| JP7137896B2 (ja) | 2017-03-24 | 2022-09-15 | レンティジェン・テクノロジー・インコーポレイテッド | 抗ｃｄ３３免疫療法によりがんを処置するための組成物および方法 |
| CN108659131B (zh) * | 2018-05-28 | 2021-09-14 | 长春力太生物技术有限公司 | 一种抗ceacam-5的单域抗体及其应用 |
| CN114040927A (zh) * | 2019-05-04 | 2022-02-11 | 印希比股份有限公司 | 结合cd33的多肽及其用途 |
-
2020
- 2020-05-07 KR KR1020217040150A patent/KR20220031554A/ko not_active Ceased
- 2020-05-07 CA CA3139096A patent/CA3139096A1/en active Pending
- 2020-05-07 AU AU2020268379A patent/AU2020268379A1/en active Pending
- 2020-05-07 JP JP2021566152A patent/JP7765291B2/ja active Active
- 2020-05-07 CN CN202080048661.5A patent/CN114206928B/zh active Active
- 2020-05-07 US US17/608,743 patent/US12552855B2/en active Active
- 2020-05-07 SG SG11202111890RA patent/SG11202111890RA/en unknown
- 2020-05-07 MA MA055907A patent/MA55907A/fr unknown
- 2020-05-07 MX MX2021013591A patent/MX2021013591A/es unknown
- 2020-05-07 EP EP20802310.1A patent/EP3966251A4/en active Pending
- 2020-05-07 WO PCT/US2020/031780 patent/WO2020227474A1/en not_active Ceased
- 2020-05-07 BR BR112021022356A patent/BR112021022356A2/pt unknown
-
2021
- 2021-11-01 IL IL287770A patent/IL287770A/en unknown
-
2025
- 2025-10-24 JP JP2025179511A patent/JP2026021386A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113784732B (zh) | 靶向bcma的工程化免疫细胞及其用途 | |
| AU2016228080B2 (en) | Reducing immune tolerance induced by PD-L1 | |
| CN113784733B (zh) | 靶向bcma的工程化免疫细胞及其用途 | |
| CN113082201B (zh) | 刺激t细胞介导的对表达抗原的细胞群的免疫应答的方法 | |
| JP7767502B2 (ja) | Ｎｋ阻害性分子を発現する遺伝子改変免疫細胞とその使用 | |
| AU2014259675B2 (en) | CS1-specific chimeric antigen receptor engineered immune effector cells | |
| EP4219693A1 (en) | Chimeric antigen receptor targeting cd7 and use thereof | |
| JP2019518425A5 (https=) | ||
| US20180223255A1 (en) | Activation and Expansion of T Cells | |
| JP2023527530A (ja) | 同種異系移植のための操作された免疫細胞 | |
| WO2015179801A1 (en) | Car based immunotherapy | |
| Pircher et al. | T cell engineering | |
| US11008556B2 (en) | Chimeric antigen receptor (CAR) and T cell receptor (TCR) modified T cells | |
| AU2020316429B2 (en) | Composition and method for adoptive immunotherapy | |
| CN110257338A (zh) | 嵌合细胞因子受体 | |
| JPWO2020227474A5 (https=) | ||
| JPWO2020227475A5 (https=) | ||
| WO2022036224A1 (en) | Chimeric antigen receptor t cells for treating autoimmunity | |
| JPWO2019241685A5 (https=) | ||
| KR20240070523A (ko) | 키메라 항원 수용체 암 면역요법 효능을 증강시키기 위한 Bcl-2의 조절 | |
| JPWO2020123938A5 (https=) | ||
| CN115501330A (zh) | 用于细胞免疫治疗的方法和组合物 | |
| Al-Khami et al. | Adoptive immunotherapy of cancer: Gene transfer of T cell specificity | |
| HK40110123A (zh) | 靶向bcma的工程化免疫细胞及其用途 | |
| HK40111221A (zh) | 调节bcl-2增强嵌合抗原受体癌症免疫疗法功效 |